Pulmonary exacerbation in adults with bronchiectasis: A consensus definition for clinical research

European Respiratory Journal

Volumn 49, Issue 6, 2017, Pages

  Hill, Adam T ^a   Haworth, Charles S ^b,x   Aliberti, Stefano ^c   Barker, Alan ^d   Blasi, Francesco ^c   Boersma, Wim ^e   Chalmers, James D ^f   de Soyza, Anthony ^g   Dimakou, Katerina ^h   Elborn, J Stuart ⁱ   Feldman, Charles ^j   Flume, Patrick ^k   Goeminne, Pieter C ^l,m   Loebinger, Michael R ⁱ   Menendez, Rosario ⁿ   Morgan, Lucy ^o   Murris, Marlene ^p   Polverino, Eva ^q   Quittner, Alexandra ^r   Ringshausen, Felix C ^s   Tino, Gregory ^t   Torres, Antoni ^q   Vendrell, Montserrat ^u   Welte, Tobias ^s   Wilson, Rob ⁱ   Wong, Conroy ^v   O'Donnell, Anne ^w,x   Aksamit, Timothy ^x   more..

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b PAPWORTH HOSPITAL   (United Kingdom)

^c UNIVERSITY OF MILAN   (Italy)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e Medical Centre Alkmaar   (Netherlands)

^f UNIVERSITY OF DUNDEE   (United Kingdom)

^g NEWCASTLE UNIVERSITY   (United Kingdom)

^h SOTIRIA GENERAL HOSPITAL   (Greece)

ⁱ ROYAL BROMPTON HOSPITAL   (United Kingdom)

^j UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^k MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^l AZ Nikolaas   (Belgium)

^m UNIVERSITY HOSPITALS LEUVEN   (Belgium)

ⁿ HOSPITAL UNIVERSITARIO LA FE   (Spain)

^o ANZAC Research Institute   (Australia)

^p SERVICE DE PNEUMOLOGIE   (France)

^q INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^r Behavioral Health and Clinical Research Program   (United States)

^s HANNOVER MEDICAL SCHOOL   (Germany)

^t UNIVERSITY OF PENNSYLVANIA   (United States)

^u HOSPITAL JOSEP TRUETA   (Spain)

^v MIDDLEMORE HOSPITAL   (New Zealand)

^w GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^x Mayo Clinic College of Medicine   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BRONCHIECTASIS; CONSENSUS DEVELOPMENT; COUGHING; DISEASE EXACERBATION; DYSPNEA; EXERCISE TOLERANCE; FATIGUE; HEMOPTYSIS; HUMAN; MALAISE; SPUTUM VOLUME; SYSTEMATIC REVIEW; ASIA; AUSTRALIA; CLINICAL TRIAL (TOPIC); CONSENSUS; DELPHI STUDY; EUROPE; LUNG; NORTH AMERICA; PATHOPHYSIOLOGY; PULMONOLOGY; SOUTH AFRICA; SPUTUM;

ASIA; AUSTRALIA; BRONCHIECTASIS; CLINICAL TRIALS AS TOPIC; CONSENSUS; COUGH; DELPHI TECHNIQUE; DISEASE PROGRESSION; DYSPNEA; EUROPE; HUMANS; LUNG; NORTH AMERICA; PULMONARY MEDICINE; SOUTH AFRICA; SPUTUM;

EID: 85030033042     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.00051-2017     Document Type: Article

References (26)

1. Pasteur MC, Bilton D, Hill AT, et al. British Thoracic Society guideline for non-CF bronchiectasis. Thorax 2010; 65: Suppl. 1, i1-i58.
2. Serisier DJ, Bilton D, De Soyza A, et al. Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial. Thorax 2013; 68: 812-817.
3. Wilson R, Welte T, Polverino E, et al. Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study. Eur Respir J 2013; 41: 1107-1115.
4. Altenburg J, de Graaff CS, Stienstra Y, et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA 2013; 309: 1251-1259.
5. Bilton D, Daviskas E, Anderson SD, et al. Phase 3 randomized study of the efficacy and safety of inhaled dry powder mannitol for the symptomatic treatment of non-cystic fibrosis bronchiectasis. Chest 2013; 144: 215-225.
6. Bilton D, Tino G, Barker AF, et al. Inhaled mannitol for non-cystic fibrosis bronchiectasis: a randomised, controlled trial. Thorax 2014; 69: 1073-1079.
7. Chalmers JD, Smith MP, McHugh BJ, et al. Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2012; 186: 657-665.
8. Kellett F, Robert NM. Nebulised 7% hypertonic saline improves lung function and quality of life in bronchiectasis. Respir Med 2011; 105: 1831-1835.
9. Mandal P, Chalmers JD, Graham C, et al. Atorvastatin as a stable treatment in bronchiectasis: a randomised controlled trial. Lancet Respir Med 2014; 2: 455-463.
10. Hernando R, Drobnic ME, Cruz MJ, et al. Budesonide efficacy and safety in patients with bronchiectasis not due to cystic fibrosis. Int J Clin Pharm 2012; 34: 644-650.
11. Lee AL, Hill CJ, Cecins N, et al. The short and long term effects of exercise training in non-cystic fibrosis bronchiectasis - a randomised controlled trial. Respir Res 2014; 15: 44.
12. Barker AF, O'Donnell AE, Flume P, et al. Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials. Lancet Respir Med 2014; 2: 738-749.
13. Martínez-García MA, Soler-Cataluña JJ, Catalán-Serra P, et al. Clinical efficacy and safety of budesonideformoterol in non-cystic fibrosis bronchiectasis. Chest 2012; 141: 461-468.
14. Murray MP, Govan JR, Doherty CJ, et al. A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2011; 183: 491-499.
15. Murray MP, Pentland JL, Hill AT. A randomised crossover trial of chest physiotherapy in non-cystic fibrosis bronchiectasis. Eur Respir J 2009; 34: 1086-1092.
16. Nicolson CH, Stirling RG, Borg BM, et al. The long term effect of inhaled hypertonic saline 6% in non-cystic fibrosis bronchiectasis. Respir Med 2012; 106: 661-667.
17. Patterson JE, Hewitt O, Kent L, et al. Acapella versus 'usual airway clearance' during acute exacerbation in bronchiectasis: a randomized crossover trial. Chron Respir Dis 2007; 4: 67-74.
18. Serisier DJ, Martin ML, McGuckin MA, et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA 2013; 309: 1260-1267.
19. Valery PC, Morris PS, Byrnes CA, et al. Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial. Lancet Respir Med 2013; 1: 610-620.
20. Wong C, Jayaram L, Karalus N, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet 2012; 380: 660-667.
21. Kapur N, Masters IB, Morris PS, et al. Defining pulmonary exacerbation in children with non-cystic fibrosis bronchiectasis. Pediatr Pulmonol 2012; 47: 68-75.
22. Haworth CS, Foweraker JE, Wilkinson P, et al. Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. Am J Respir Crit Care Med 2014; 189: 975-982.
23. Bilton D, Henig N, Morrissey B, et al. Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis. Chest 2006; 130: 1503-1510.
24. Murphy MK, Black NA, Lamping DL, et al. Consensus development methods, and their use in clinical guideline development. Health Technol Assess 1998; 2: 1-88.
25. Murray MP, Turnbull K, Macquarrie S, et al. Assessing response to treatment of exacerbations of bronchiectasis in adults. Eur Respir J 2009; 33: 312-318.
26. Vendrell M, de Gracia J, Olveira C, et al. Diagnostico y tratamiento de las bronquiectasias. SEPAR. [Diagnosis and treatment of bronchiectasis. Spanish Society of Pneumology and Thoracic Surgery.] Arch Bronconeumol 2008; 44: 629-640.